From GlobeNewswire: 2025-02-06 19:51:10

Sionna Therapeutics Inc. has priced its upsized initial public offering of 10,588,233 shares of common stock at $18.00 per share. The company granted underwriters a 30-day option to purchase up to 1,588,234 additional shares. The gross proceeds are expected to be approximately $191 million. The offering is expected to close on February 10, 2025. Sionna’s shares will trade on the Nasdaq Global Market under the ticker symbol “SION.” The company aims to develop medicines for cystic fibrosis that normalize the function of the CFTR protein, focusing on the F508del genetic mutation.

Goldman Sachs & Co. LLC, TD Cowen, Stifel, and Guggenheim Securities are acting as joint book-running managers for the offering. Sionna Therapeutics is a clinical-stage biopharmaceutical company dedicated to revolutionizing the treatment of cystic fibrosis by developing medicines to restore CFTR function. The company’s goal is to improve clinical outcomes and quality of life for individuals with CF by stabilizing CFTR’s nucleotide-binding domain 1. Forward-looking statements in the press release should be considered alongside risks and uncertainties related to market conditions and pharmaceutical product development.



Read more at GlobeNewswire: Sionna Therapeutics Prices Upsized Initial Public Offering